Skip to main content Accessibility help
×
Hostname: page-component-848d4c4894-4hhp2 Total loading time: 0 Render date: 2024-05-01T02:46:43.419Z Has data issue: false hasContentIssue false

4 - The clinical virology of pediatric HIV disease

from Part I - Scientific basis of pediatric HIV care

Published online by Cambridge University Press:  03 February 2010

Paul Palumbo
Affiliation:
Departments of Pediatrics and of Biochemistry and Molecular Biology, UMDNJ-New Jersey Medical School, Newark, NJ
Steven L. Zeichner
Affiliation:
National Cancer Institute, Bethesda, Maryland
Jennifer S. Read
Affiliation:
National Cancer Institute, Bethesda, Maryland
Get access

Summary

The advent of potent antiretroviral therapy and effective prophylaxis for opportunistic infections has created a clear need for early diagnosis of HIV infection in pediatric patients and for methods of monitoring disease course and response to therapy. The field has undergone substantial progress within the past decade and innovations continue to emerge. Diagnostic issues will be addressed initially in this chapter, followed by virologic approaches for monitoring disease course and response to therapy.

Virologic assays for the diagnosis of pediatric HIV infection

Serology

Reports of the isolation of a human immunodeficiency virus (LAV; HTLV-III; later to be known as HIV-1) in 1984 [1–4] were quickly followed by the development of enzyme immunoassays (EIAs) capable of detecting a human antibody response to infection [5, 6]. It soon became clear that reactive EIAs required confirmation by Western blot to verify that the EIA-detected immune response was HIV-specific. While confirmation is essential for all EIA-reactive specimens, it is particularly important in low-risk populations where the positive predictive value of EIA is relatively low [7–10]. This issue has recently resurfaced in the context of rapid antibody tests, which can provide test results soon after the specimen is obtained at the same visit [11]. These rapid diagnostic tests can be performed in 10–30 minutes, an appealing feature for relatively non-compliant populations and for pregnant women at labor and delivery with an unknown HIV infection status.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Barre-Sinoussi, F., Chermann, J. C., Rey, F.. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (Acquired Immune Deficiency Syndrome). Science 220 (1983), 868–71CrossRefGoogle Scholar
Gallo, R. C., Sarin, P. S., Gelmann, E. P.. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (Acquired Immune Deficiency Syndrome). Science 220 (1983), 865–7CrossRefGoogle Scholar
Gallo, R. C., Salahuddin, S. Z., Popovic, M.. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with Acquired Immune Deficiency Syndrome and at risk for Acquired Immune Deficiency Syndrome. Science 224 (1984), 500–3CrossRefGoogle Scholar
Levy, J. A., Hoffman, J. D., Kramer, S. M.. Isolation of lymphocytopathic retroviruses from San Francisco patients with Acquired Immune Deficiency Syndrome. Science 224 (1984), 840–2CrossRefGoogle Scholar
Kalyanaraman, V. S., Cabradilla, C. D., Getchell, J. P.. Antibodies to the core protein of lymphadenopathy-associated virus (LAV) in patients with Acquired Immune Deficiency Syndrome. Science 225 (1984), 321–3CrossRefGoogle Scholar
Sarngadharan, M. G., Popovic, M., Bruch, L., Schupbach, J. & Gallo, R. C.Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with Acquired Immune Deficiency Syndrome. Science 224 (1984), 506–8CrossRefGoogle Scholar
Centers for Disease Control. Interpretation and use of the western blot assay for serodiagnosis of human immunodeficiency virus type 1 infections. J. Am. Med. Assoc. 262 (1989), 3395–7CrossRef
Centers for Disease Control. Interpretation and use of the western blot assay for serodiagnosis of human immunodeficiency virus type 1 infections. Morb. Mortal. Wkly. Rep. 38 (1989), 1–7
Centers for Disease Control. Interpretive criteria used to report western blot results for Human Immunodeficiency Virus-1- antibody testing—United States. MMWR 40 (1991), 692–5
Constantine, N. T.Serologic tests for the retroviruses: approaching a decade of evolution. Acquired Immune Deficiency Syndrome 7 (1993), 1–13Google Scholar
Centers for Disease Control. Human Immunodeficiency Virus counseling and testing using rapid tests. MMWR 47 (1998), 211–5
Stetler, H. C., Granade, T. C., Nunez, C. A.. Field evaluation of rapid Human Immunodeficiency Virus serologic tests for screening and confirming Human Immunodeficiency Virus-1 infection in Honduras. Acquired Immune Deficiency Syndrome 11 (1997), 369–75Google ScholarPubMed
Connor, E., Wang, Z., Stephens, R.. Enzyme immunoassay for detection of human immunodeficiency virus-specific immunoglobulin A antibodies. J. Clin. Microbiol. 31 (1993) 681–4Google ScholarPubMed
Kliks, S. C., Wara, D. W., Landers, D. V. & Levy, J. A.Features of Human Immunodeficiency Virus-1 that could influence maternal-child transmission. J. Am. Med. Assoc. 272 (1994), 467–74CrossRefGoogle ScholarPubMed
Martin, N. L., Levy, J. A., Legg, H., Weintrub, P. S., Cowan, M. J. & Wara, D. W.Detection of infection with human immunodeficiency virus (Human Immunodeficiency Virus) type 1 in infants by an anti-Human Immunodeficiency Virus immunoglobulin A assay using recombinant proteins. J. Pediatr. 118 (1991), 354–8CrossRefGoogle Scholar
McIntosh, K., Comeau, A. M., Wara, D.. The utility of ImmunoglobulinA antibody to human immunodeficiency virus type 1 in early diagnosis of vertically transmitted infection. National Institute of Allergy and Infectious Diseases and National Institute of Child Health and Human Development Women and Infants Transmission Study Group. Arch. Pediatr. Adolesc. Med. 150 (1996), 598–602CrossRefGoogle Scholar
Quinn, T. C., Kline, R. L., Halsey, N.. Early diagnosis of perinatal Human Immunodeficiency Virus infection by detection of viral- specific ImmunoglobulinA antibodies. J. Am. Med. Assoc. 266 (1991), 3439–42CrossRefGoogle Scholar
Weiblen, B. J., Lee, F. K., Cooper, E. R.. Early diagnosis of Human Immunodeficiency Virus infection in infants by detection of ImmunoglobulinA Human Immunodeficiency Virus antibodies. Lancet 335 (1990), 988–90CrossRefGoogle Scholar
Alimenti, A., O' Neill, M., Sullivan, J. L. & Luzuriaga, K.Diagnosis of vertical human immunodeficiency virus type 1 infection by whole blood culture. J. Infect. Dis. 166 (1992), 1146–8CrossRefGoogle ScholarPubMed
Borkowsky, W., Krasinski, K., Pollack, H., Hoover, W., Kaul, A. & Ilmet-Moore, T.Early diagnosis of human immuno-deficiency virus infection in children less than 6 months of age: comparison of polymerase chain reaction, culture, and plasma antigen capture techniques. J. Infect. Dis. 166 (1992), 616–9CrossRefGoogle ScholarPubMed
Hollinger, F. B., Bremer, J. W., Myers, L. E., Gold, J. W. & McQuay, L.Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the Acquired Immune Deficiency Syndrome Clinical Trials Group. The National Institutes of Health/National Institute of Allergy and Infectious Diseases/DAIDS/Acquired Immune Deficiency Syndrome Clinical Trials Group Virology Laboratories. J. Clin. Microbiol. 30 (1992), 1787–94Google Scholar
Jackson, J. B., Coombs, R. W., Sannerud, K., Rhame, F. S. & Balfour, H. H. Jr.Rapid and sensitive viral culture method for human immunodeficiency virus type 1. J. Clin. Microbiol. 26 (1988), 1416–8Google ScholarPubMed
Nishanian, P., Huskins, K. R., Stehn, S., Detels, R. & Fahey, J. L.A simple method for improved assay demonstrates that Human Immunodeficiency Virus p24 antigen is present as immune complexes in most sera from Human Immunodeficiency Virus-infected individuals. J. Infect. Dis. 162 (1990), 21–8CrossRefGoogle Scholar
Quinn, T. C., Kline, R., Moss, M. W., Livingston, R. A. & Hutton, N.Acid dissociation of immune complexes improves diagnostic utility of p24 antigen detection in perinatally acquired human immunodeficiency virus infection. J. Infect. Dis. 167 (1993), 1193–6CrossRefGoogle ScholarPubMed
Schupbach, J. & Boni, J.Quantitative and sensitive detection of immune-complexed and free Human Immunodeficiency Virus antigen after boiling of serum. J. Virol. Methods 43 (1993), 247–56CrossRefGoogle ScholarPubMed
Schupbach, J., Boni, J., Tomasik, Z., Jendis, J., Seger, R. & Kind, C.Sensitive detection and early prognostic significance of p24 antigen in heat-denatured plasma of human immuno-deficiency virus type 1-infected infants. Swiss Neonatal Human Immunodeficiency Virus Study Group. J. Infect. Dis. 170 (1994) 318–24CrossRefGoogle Scholar
Schupbach, J., Flepp, M., Pontelli, D., Tomasik, Z., Luthy, R. and Boni, J.Heat-mediated immune complex dissociation and enzyme-linked immunosorbent assay signal amplification render p24 antigen detection in plasma as sensitive as Human Immunodeficiency Virus-1 Ribonucleic Acid detection by polymerase chain reaction. Acquired Immune Deficiency Syndrome 10 (1996), 1085–90Google ScholarPubMed
Boni, J., Opravil, M., Tomasik, Z.. Simple monitoring of antiretroviral therapy with a signal-amplification-boosted Human Immunodeficiency Virus-1 p24 antigen assay with heat-denatured plasma. Acquired Immune Deficiency Syndrome 11 (1997), F47–52Google ScholarPubMed
Mullis, K., Faloona, F., Scharf, S., Saiki, R., Horn, G. & Erlich, H.Specific enzymatic amplification of Deoxyribonucleic Acid in vitro: the polymerase chain reaction. Cold Spring Harb. Symp. Quant. Biol. 51: 1(1986), 263–73CrossRefGoogle ScholarPubMed
Jackson, J. B., Drew, J., Lin, H. J.. Establishment of a quality assurance program for human immunodeficiency virus type 1 Deoxyribonucleic Acid polymerase chain reaction assays by the Acquired Immune Deficiency Syndrome Clinical Trials Group. Acquired Immune Deficiency Syndrome Clinical Trials Group Polymerase Chain Reaction Working Group, and the Acquired Immune Deficiency Syndrome Clinical Trials Group Polymerase Chain Reaction Virology Laboratories. J. Clin. Microbiol. 31 (1993), 3123–8Google Scholar
Cassol, S. A., Lapoint, N., Salas, T.. Diagnosis of vertical Human Immunodeficiency Virus-1 transmission using the Polymerase Chain Reaction and dried blood spot speci-mens. J. Acquir. Immune Defic. Syndr. 5 (1992), 113–19Google Scholar
Cassol, S., Salas, T., Gill, M. J.. Stability of dried blood spot specimens for detection of Human Immunodeficiency Virus Deoxyribonucleic Acid by Polymerase Chain Reaction. J. Clin. Microbiol. 30 (1992), 3039–42Google ScholarPubMed
Comeau, A. M., Hsu, H. W., Schwerzler, M., Mushinsky, G. & Grady, G. F.Detection of Human Immunodeficiency Virus in specimens from newborn screening programs [letter]. New Engl. J. Med. 326 (1992), 1703Google Scholar
Comeau, A. M., Hsu, H. W., Schwerzler, M.. Identifying human immunodeficiency virus infection at birth: application of polymerase chain reaction to Guthrie cards. J. Pediatr. 123 (1993), 252–8CrossRefGoogle ScholarPubMed
Comeau, A. M., Su, X., Muchinsky, G., Pan, D., Gerstel, J. & Grady, G. F. Quality-controlled pooling strategies for nucleic-acid based Human Immunodeficiency Virus screening: using Polymerase Chain Reaction as a primary screen on dried blood spot specimens in population studies. In 5th Conference on Retroviruses and Opportunistic Infections. Chicago, Interleukin, 1998
Bremer, J. W., Lew, J. F., Cooper, E.. Diagnosis of infection with human immunodeficiency virus type 1 by a Deoxyribonucleic Acid polymerase chain reaction assay among infants enrolled in the Women and Infants' Transmission Study. J. Pediatr. 129 (1996), 198–207CrossRefGoogle Scholar
Owens, D. K., Holodniy, M., McDonald, T. W., Scott, J. & Sonnad, S.A meta-analytic evaluation of the polymerase chain reaction for the diagnosis of Human Immunodeficiency Virus infection in infants. J. Am. Med. Assoc. 275 (1996), 1342–8CrossRefGoogle Scholar
The Working Group on Antiretroviral Therapy and Medical Management of Human Immunodeficiency Virus-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric Human Immunodeficiency Virus Infection, 2001 (http://www.hivatis.org)
Stanley, S., Ostrowski, M. A., Justement, J. S.. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. New Engl. J. Med. 334 (1996), 1222–30CrossRefGoogle ScholarPubMed
Staprans, S. I., Hamilton, B. L., Follansbee, S. E.. Activation of virus replication after vaccination of Human Immunodeficiency Virus-1-infected individuals. J. Exp. Med. 182 (1995), 1727–37CrossRefGoogle Scholar
Ramilo, O., Hicks, P. J., Borvak, J.. T cell activation and human immunodeficiency virus replication after influenza immunization of infected children. Pediatr. Infect. Dis. J. 15 (1996), 197–203CrossRefGoogle ScholarPubMed
O' Brien, W., Grovit-Ferbas, K., Namazi, A.. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 86 (1995), 1082–9Google Scholar
Kroon, F. P., Dissel, J. T., Jong, J. C. & Furth, R.Antibody response to influenza, tetanus and pneumococcal vaccines in Human Immunodeficiency Virus-seropositive individuals in relation to the number of Cluster of Differentiation4+ lymphocytes. Acquired Immune Deficiency Syndrome 8 (1994), 469–76Google Scholar
Brichacek, B., Swindells, S., Janoff, E. N., Pirruccello, S. & Stevenson, M.Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine. J. Infect. Dis. 174 (1996), 1191–9CrossRefGoogle ScholarPubMed
Ho, D. D., Neumann, A. U., Perelson, A. S., Chen, W., Leonard, J. M. & Markowitz, M.Rapid turnover of plasma virions and Cluster of Differentiation4 lymphocytes in Human Immunodeficiency Virus-1 infection. Nature 373 (1995), 123–6CrossRefGoogle Scholar
Wei, X., Ghosh, S. K., Taylor, M. E.. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373 (1995), 117–22CrossRefGoogle ScholarPubMed
Wong, J. K., Hezareh, M., Gunthard, H. F.. Recovery of replication-competent Human Immunodeficiency Virus despite prolonged suppression of plasma viremia. Science 278 (1997), 1291–5CrossRefGoogle ScholarPubMed
Finzi, D., Hermankova, M., Pierson, T.. Identification of a reservoir for Human Immunodeficiency Virus-1 in patients on highly active antiretroviral therapy. Science 278 (1997), 1295–300CrossRefGoogle ScholarPubMed
Chun, T., Stuyver, L., Mizell, S. B.. Presence of an indu-cible Human Immunodeficiency Virus-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 94 (1997), 13193–7CrossRefGoogle ScholarPubMed
Chun, T. W., Carruth, L., Finzi, D.. Quantification of latent tissue reservoirs and total body viral load in Human Immunodeficiency Virus-1 infection. Nature 387 (1997), 183–8CrossRefGoogle Scholar
Persaud, D., Pierson, T., Ruff, C.. A stable latent reservoir for Human Immunodeficiency Virus-1 in resting Cluster of Differentiation4(+) T lymphocytes in infected children. J. Clin. Invest. 105 (2000), 995–1003CrossRefGoogle Scholar
Mellors, J. W., Rinaldo, C. R. Jr., Gupta, P., White, R. M., Todd, J. A. & Kingsley, L. A.Prognosis in Human Immunodeficiency Virus-1 infection predicted by the quantity of virus in plasma. Science 272 (1996), 1167–70CrossRefGoogle ScholarPubMed
Coombs, R. W., Welles, S. L., Hooper, C.. Association of plasma human immunodeficiency virus type 1 Ribonucleic Acid level with risk of clinical progression in patients with advanced infection. Acquired Immune Deficiency Syndrome Clinical Trials Group (Acquired Immune Deficiency Syndrome Clinical Trials Group) 116B/117 Study Team. Acquired Immune Deficiency Syndrome Clinical Trials Group Virology Committee Resistance and Human Immunodeficiency Virus-1 Ribonucleic Acid Working Groups. J. Infect. Dis. 174 (1996), 704–12CrossRefGoogle Scholar
Welles, S. L., Jackson, J. B., Yen-Lieberman, B.. Prognostic value of plasma human immunodeficiency virus type 1 (Human Immunodeficiency Virus-1) Ribonucleic Acid levels in patients with advanced Human Immunodeficiency Virus-1 disease and with little or no prior zidovudine therapy. Acquired Immune Deficiency Syndrome Clinical Trials Group Protocol 116A/116B/117 Team. J. Infect. Dis. 174 (1996), 696–703CrossRefGoogle ScholarPubMed
Palumbo, P. E., Kwok, S., Waters, S.. Viral measurement by polymerase chain reaction-based assays in human immuno-deficiency virus-infected infants. J. Pediatr. 126 (1995), 592–5CrossRefGoogle ScholarPubMed
Shearer, W. T., Quinn, T. C., LaRussa, P.. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N. Engl. J. Med. 336 (1997), 1337–42CrossRefGoogle ScholarPubMed
Mofenson, L. M., Korelitz, J., Meyer, W. A. 3rd.. The relationship between serum human immunodeficiency virus type 1 (Human Immunodeficiency Virus-1) Ribonucleic Acid level, Cluster of Differentiation4 lymphocyte percent, and long-term mortality risk in Human Immunodeficiency Virus-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. J. Infect. Dis. 175 (1997), 1029–38CrossRefGoogle Scholar
Abrams, E. J., Weedon, J., Steketee, R. W.. Association of human immunodeficiency virus (Human Immunodeficiency Virus) load early in life with disease progression among Human Immunodeficiency Virus-infected infants. New York City Perinatal Human Immunodeficiency Virus Transmission Collaborative Study Group. J. Infect. Dis. 178 (1998), 101–8CrossRefGoogle Scholar
Zeichner, S. L., Palumbo, P., Feng, Y.. Rapid telomere shortening in Children. Blood 93 (1999), 2824–30Google ScholarPubMed
Krogstad, P., Uittenbogaart, C. H., Dickover, R., Bryson, Y. J., Plaeger, S. & Garfinkel, A.Primary Human Immunodeficiency Virus infection of infants: the effects of somatic growth on lymphocyte and virus dynamics. Clin. Immunol. 92 (1999), 25–33CrossRefGoogle ScholarPubMed
Palumbo, P. E., Raskino, C., Fiscus, S.. Predictive value of quantitative plasma Human Immunodeficiency Virus Ribonucleic Acid and Cluster of Differentiation4+ lymphocyte count in Human Immunodeficiency Virus-infected infants and children. J. Am. Med. Assoc. 279 (1998), 756–61CrossRefGoogle Scholar
Lindsey, J. C., Hughes, M. D., McKinney, R. E.. Treatment-mediated changes in human immunodeficiency virus (Human Immunodeficiency Virus) type 1 Ribonucleic Acid and Cluster of Differentiation4 cell counts as predictors of weight growth failure, cognitive decline, and survival in Human Immunodeficiency Virus-infected children. J. Infect. Dis. 182 (2000), 1385–93CrossRefGoogle Scholar
Sharland, M., Gibb, D. & Giaquinto, C.Current evidence for the use of paediatric antiretroviral therapy — a The Pediatric European Network for the Treatment of Acquired Immune Deficiency Syndrome analysis. Paediatric European Network for the Treatment of Acquired Immune Deficiency Syndrome Steering Committee. Eur. J. Pediatr. 159 (2000), 649–56CrossRefGoogle Scholar
Steketee, R. W., Abrams, E. J., Thea, D. M.. Early detection of perinatal human immunodeficiency virus (Human Immunodeficiency Virus) type 1 infection using Human Immunodeficiency Virus Ribonucleic Acid amplification and detection. New York City Perinatal Human Immunodeficiency Virus Transmission Collaborative Study. J. Infect. Dis. 175 (1997), 707–11CrossRefGoogle ScholarPubMed
Delamare, C., Burgard, M., Mayaux, M. J.. Human Immunodeficiency Virus-1 Ribonucleic Acid detection in plasma for the diagnosis of infection in neonates. The French Pediatric Human Immunodeficiency Virus Infection Study Group. J. Acquired Immune Deficiency Syndrome Hum. Retrovirol. 15 (1997), 121–5CrossRefGoogle Scholar
Premack, B. A.& Schall, T. J.Chemokine receptors: gateways to inflammation and infection. Nat. Med. 2 (1996), 1174–8CrossRefGoogle ScholarPubMed
Cocchi, F., DeVico, A. L., Garzino-Demo, A., Arya, S. K., Gallo, R. C. & Lusso, P.Identification of RANTES, Macrophage Inflammatory Protein-1 alpha, and Macrophage Inflammatory Protein-1 beta as the major Human Immunodeficiency Virus- suppressive factors produced by Cluster of Differentiation8+ T cells. Science 270 (1995), 1811–5CrossRefGoogle Scholar
Feng, Y., Broder, C. C., Kennedy, P. E. & Berger, E. A.Human Immunodeficiency Virus-1 entry cofactor: functional cDeoxyribonucleic Acid cloning of a seven-transmembrane, G protein-coupled receptor. Science 272 (1996), 872–7CrossRefGoogle ScholarPubMed
Berson, J. F., Long, D., Doranz, B. J., Rucker, J., Jirik, F. R. & Doms, R. W.A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immuno-deficiency virus type 1 strains. J. Virol. 70 (1996), 6288–95Google Scholar
Deng, H., Liu, R., Ellmeier, W.. Identification of a major co-receptor for primary isolates of Human Immunodeficiency Virus-1. Nature 381 (1996), 661–6CrossRefGoogle Scholar
Doranz, B. J., Rucker, J., Yi, Y.. A dual-tropic primary Human Immunodeficiency Virus-1 isolate that uses fusin and the beta- chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85 (1996), 1149–58CrossRefGoogle ScholarPubMed
Dragic, T., Litwin, V., Allaway, G. P.. Human Immunodeficiency Virus-1 entry into Cluster of Differentiation4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381 (1996), 667–73CrossRefGoogle Scholar
Alkhatib, G., Combadiere, C., Broder, C. C.. CC CKR5: a RANTES, Macrophage Inflammatory Protein-1alpha, Macrophage Inflammatory Protein-1beta receptor as a fusion cofactor for macrophage-tropic Human Immunodeficiency Virus-1. Science 272 (1996), 1955–8CrossRefGoogle Scholar
Choe, H., Farzan, M., Sun, Y.. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary Human Immunodeficiency Virus-1 isolates. Cell 85 (1996), 1135–48CrossRefGoogle Scholar
Liu, R., Paxton, W. A., Choe, S.. Homozygous defect in Human Immunodeficiency Virus-1 coreceptor accounts for resistance of some multiply-exposed individuals to Human Immunodeficiency Virus-1 infection. Cell 86 (1996), 367–77CrossRefGoogle Scholar
Smith, M. W., Dean, M., Carrington, M.. Contrasting genetic influence of CCR2 and CCR5 variants on Human Immunodeficiency Virus-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter Acquired Immune Deficiency Syndrome Cohort Study (Multicenter Acquired Immune Deficiency Syndrome Cohort Study), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science 277 (1997), 959–65CrossRefGoogle ScholarPubMed
Dean, M., Carrington, M., Winkler, C.. Genetic restriction of Human Immunodeficiency Virus-1 infection and progression to Acquired Immune Deficiency Syndrome by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter Acquired Immune Deficiency Syndrome Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 273 (1996), 1856–62CrossRefGoogle ScholarPubMed
Zimmerman, P. A., Buckler-White, A., Alkhatib, G.. Inherited resistance to Human Immunodeficiency Virus-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol. Med. 3 (1997), 23–36Google ScholarPubMed
Michael, N. L., Chang, G., Louie, L. G.. The role of viral phenotype and CCR-5 gene defects in Human Immunodeficiency Virus-1 transmission and disease progression. Nat. Med. 3 (1997), 338–40CrossRefGoogle ScholarPubMed
Biti, R., French, R., Young, J., Bennetts, B., Stewart, G. & Liang, T.Human Immunodeficiency Virus-1 infection in an individual homozygous for the CCR5 deletion allele. Nat. Med. 3 (1997), 252–3CrossRefGoogle Scholar
Wang, B., Palasanthiran, P., Zeigler, J., Cunningham, A. & Saksena, N. K.CCR5-delta 32 gene deletion in Human Immunodeficiency Virus-1 infected patients [letter]. Lancet 350 (1997), 742CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×